References
- Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996; 68: 109–182
- Blackwood E M, Eisenman R N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251: 1211–1217
- Billin A N, Eilers A L, Queva C, Ayer D E. Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors. J Biol Chem 1999; 274: 36344–36350
- Gallant P. Myc/Max/Mad in invertebrates: the evolution of the Max network. Curr Top Microbiol Immunol 2006; 302: 235–253
- Ayer D E, Kretzner L, Eisenman R N. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72: 211–222
- Zervos A S, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72: 223–232
- Hurlin P J, Queva C, Eisenman R N. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev 1997; 11: 44–58
- Edelhoff S, Ayer D E, Zervos A S, Steingrimsson E, Jenkins N A, Copeland N G, et al. Mapping of two genes encoding members of a distinct subfamily of MAX interacting proteins: MAD to human chromosome 2 and mouse chromosome 6, and MXI1 to human chromosome 10 and mouse chromosome 19. Oncogene 1994; 9: 665–668
- Roy B, Reisman D. Inducible expression of Mad accelerates growth arrest of serum deprived human glioblastoma cells. Cell Biol Int 1995; 19: 307–313
- Chen J, Willingham T, Margraf L R, Schreiber-Agus N, DePinho R A, Nisen P D. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat Med 1995; 1: 638–643
- Prochownik E V, Eagle Grove L, Deubler D, Zhu X L, Stephenson R A, Rohr L R, et al. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 1998; 22: 295–304
- Li X J, Wang D Y, Zhu Y, Guo R J, Wang X D, Lubomir K, et al. Mxi1 mutations in human neurofibrosarcomas. Jpn J Cancer Res 1999; 90: 740–746
- Sommer A, Waha A, Tonn J, Sorensen N, Hurlin P J, Eisenman R N, et al. Analysis of the Max-binding protein MNT in human medulloblastomas. Int J Cancer 1999; 82: 810–816
- Nigro C L, Venesio T, Reymond A, Meroni G, Alberici P, Cainarca S, et al. The human ROX gene: genomic structure and mutation analysis in human breast tumors. Genomics 1998; 49: 275–282
- Takahashi T, Konishi H, Kozaki K, Osada H, Saji S, Takahashi T, et al. Molecular analysis of a Myc antagonist, ROX/Mnt, at 17p13.3 in human lung cancers. Jpn J Cancer Res 1998; 89: 347–351
- Ayer D E, Lawrence Q A, Eisenman R N. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 1995; 80: 767–776
- Sommer A, Hilfenhaus S, Menkel A, Kremmer E, Seiser C, Loidl P, et al. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. Curr Biol 1997; 7: 357–365
- Koskinen P J, Ayer D E, Eisenman R N. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein – protein interactions. Cell Growth Differ 1995; 6: 623–629
- Roussel M F, Ashmun R A, Sherr C J, Eisenman R N, Ayer D E. Inhibition of cell proliferation by the Mad1 transcriptional repressor. Mol Cell Biol 1996; 16: 2796–2801
- Eilers A L, Billin A N, Liu J, Ayer D E. A 13-amino acid amphipathic alpha-helix is required for the functional interaction between the transcriptional repressor Mad1 and mSin3A. J Biol Chem 1999; 274: 32750–32756
- Hara F, Suzuki T, Saito M, Hikino T, Fukushima T, Oyama T, et al. Non-isotopic single strand conformation polymorphism (PCR-SSCP) with subsequent direct sequencing after silver staining. Pathol Int 1994; 44: 815–816
- Foley K P, Eisenman R N. Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim Biophys Acta 1999; 1423: M37–M47
- Kawamata N, Park D, Wilczynski S, Yokota J, Koeffler H P. Point mutations of the Mxil gene are rare in prostate cancers. Prostate 1996; 29: 191–193
- Bartsch D, Peiffer S L, Kaleem Z, Wells S A, Jr, Goodfellow P J. Mxi1 tumor suppressor gene is not mutated in primary pancreatic adenocarcinoma. Cancer Lett 1996; 102: 73–76
- Wechsler D S, Shelly C A, Petroff C A, Dang C V. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 1997; 57: 4905–4912
- Ferre-D'Amare A R, Prendergast G C, Ziff E B, Burley S K. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature 1993; 363: 38–45
- Schreiber-Agus N, Meng Y, Hoang T, Hou H, Jr, Chen K, Greenberg R, et al. Role of Mxi1 in aging organ systems and the regulation of normal and neoplastic growth. Nature 1998; 393: 483–487
- Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990; 55: 133–270
- Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990; 55: 133–270